Acinetobacter baumannii 의 임상적 동정에서 자동 및 수동 시스템으로부터의 항생제 감수성 검사의 오류
Errors of Antibiotic Susceptibility Testing from Automated and Manual Systems in Clinical Isolates of Acinetobacter baumannii
0
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Acinetobacter baumannii is an aerobic, gram-negative and glucose-non-fermenting bacterium, which has emerged as a serious opportunistic pathogen. Many clinical microbiology laboratories use the Vitek 2 system for the routine antimicrobial susceptibility testing process, including testing on A. baumannii isolates. However, in case of amikacin, it is now recommended to perform additional antimicrobial susceptibility testing for A. baumannii strains due to the relatively lower minimum inhibitory concentration (MIC) in the Vitek 2 system compared to conventional reference methods. In our study, we assessed MIC for amikacin susceptibility testing of A. baumannii isolates in the Vitek 2 system, the agar dilution, Etest, and disk diffusion method. We collected 40 gentamicin-resistant, A. baumannii strains (amikacin MIC by Vitek 2:≤2 μg/mL, 2 isolates; 4 μg/mL, 34 isolates; 8 μg/mL, 4 isolates) from a University hospital and compared the Vitek 2 system to other reference methods for testing susceptibility to amikacin. The Vitek 2 system showed major errors in all of the 40 isolates, yielding a low MIC. The results of our study strongly suggested that the Vitek 2 system was not a reliable method to test the MICs of gentamicin; ranging from ≥ 16 μg/mL for amikacin susceptibility. Other tests, such as agar dilution, Etest, or disk diffusion methods, should be paralleled to determine the MIC of amikacin in A. baumannii.
Abstract
Acinetobacter baumannii is an aerobic, gram-negative and glucose-non-fermenting bacterium, which has emerged as a serious opportunistic pathogen. Many clinical microbiology laboratories use the Vitek 2 system for the routine antimicrobial susceptibility testing process, including testing on A. baumannii isolates. However, in case of amikacin, it is now recommended to perform additional antimicrobial susceptibility testing for A. baumannii strains due to the relatively lower minimum inhibitory concentration (MIC) in the Vitek 2 system compared to conventional reference methods. In our study, we assessed MIC for amikacin susceptibility testing of A. baumannii isolates in the Vitek 2 system, the agar dilution, Etest, and disk diffusion method. We collected 40 gentamicin-resistant, A. baumannii strains (amikacin MIC by Vitek 2:≤2 μg/mL, 2 isolates; 4 μg/mL, 34 isolates; 8 μg/mL, 4 isolates) from a University hospital and compared the Vitek 2 system to other reference methods for testing susceptibility to amikacin. The Vitek 2 system showed major errors in all of the 40 isolates, yielding a low MIC. The results of our study strongly suggested that the Vitek 2 system was not a reliable method to test the MICs of gentamicin; ranging from ≥ 16 μg/mL for amikacin susceptibility. Other tests, such as agar dilution, Etest, or disk diffusion methods, should be paralleled to determine the MIC of amikacin in A. baumannii.
참고문헌 (13)
- Bergogne-Berezin E, "Acinetobacter spp. as nosocomial pathogens: microbiological, clinical, and epidemiological features", Clin Microbiol Rev, 9, pp.148~165 (1996)
- CLSI, "Performance standards for antimicrobial susceptibility testing; sixteenth informational supplement", Clinical and Laboratory Standards Institute, ~ (2010)
- D'Agata EM, "Rapidly rising prevalence of nosocomial multidrug- resistant, Gram-negative bacilli: a 9-year surveillance study", Infect Control Hosp Epidemiol, 25, pp.842~846 (2004)
- Fiebelkorn KR, "Practical disk diffusion method for detection of inducible clindamycin resistance in Staphylococcus aureus and coagulase-negative staphylococci", J Clin Microbiol, 41, pp.4740~4744 (2003)
- Foxman B, "Epidemiology of urinary tract infections: incidence, morbidity, and economic costs", Am J Med, 113, pp.5~13 (2002)
- Hsieh WS, "Evaluation of the VITEK 2 cards for identification and antimicrobial susceptibility testing of non-glucose-fermenting Gram-negative bacilli", APMIS, 117, pp.241~247 (2009)
- 김수정, "대구지역병원에서 분리된 Acinetobacter baumannii와 Pseudomonas aeruginosa의 항생제 내성현황", 대한임상검사과학회지, 40(2), pp.75~79 (2008), 대한임상검사과학회
- Ko KS, "High rates of resistance to colistin and polymyxin B in subgroups of Acinetobacter baumannii isolates from Korea", J Antimicrob Chemother, 60, pp.1163~1167 (2007)
- 구선회, "Genetic Basis of Multidrug-resistant Acinetobacter baumannii Clinical Isolates from Three University Hospitals in Chungcheong Province, Korea", Annals of Laboratory Medicine, 30(5), pp.498~506 (2010), 대한진단검사의학회
- Ligozzi M, "Evaluation of the VITEK 2 system for identification and antimicrobial susceptibility testing of medically relevant gram-positive cocci", J Clin Microbiol, 40, pp.1681~1686 (2002)
- Srinivasan VB, "Genetic relatedness and molecular characterization of multidrug resistant Acinetobacter baumannii isolated in central Ohio, USA", Ann Clin Microbiol Antimicrob, 8, pp.21~30 (2009)
- 박동진, "Evaluation of the Vitek 2 AST-N055 Card for the Susceptibility Testing of Acinetobacter baumannii Isolates to Amikacin", Annals of Clinical Microbiology, 12(3), pp.144~145 (2009), 대한임상미생물학회
- Woo HY, "Evaluation of VITEK-2 system for antibiotic susceptibility test of Streptococcus pneumoniae", Korean J Clin Pathol, 21, pp.129~134 (2001)